DANA-FARBER CANCER INSTITUTE was awarded a $900,000 grant from the Ovarian Cancer Research Fund to test new combinations of targeted drugs against the disease.
THE NATIONAL COALITION FOR CANCER RESEARCH elected members to its board of directors. Wendy Selig was elected president.
AVEO Oncology and Astellas Pharma Inc. discontinued a phase II study of tivozanib in locally recurrent or metastatic triple-negative breast cancer due to insufficient enrollment.
CVS Caremark plans to stop selling cigarettes and other tobacco products at more than 7,600 CVS/pharmacy stores by Oct. 1.
Responding to questions from The Cancer Letter, Jim Newman, director of external communications at MD Anderson, confirmed that the presentation obtained by The Cancer Letter was prepared under a contract by McKinsey & Company.
You might think of this as an event isolated to Columbus or central Ohio:
THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO and Quest Diagnostics formed a collaboration to research advanced diagnostics in the field of precision medicine. Initial clinical areas of focus include autism, oncology, neurology and women's health.
FDA notified Cell Therapeutics Inc. that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.
ANGELA DAVIES was appointed chief medical officer of Champions Oncology.
THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center received a pledge of $15 million to support breast cancer research from The Vera Bradley Foundation.
